Branched-chain α-keto acids accumulating in maple syrup urine disease induce reorganization of phosphorylated GFAP in C6-glioma cells

Metabolic Brain Disease

Volumn 20, Issue 3, 2005, Pages 205-217

  Funchal, Cláudia ^a   Dos Santos, André Quincozes ^a   Jacques Silva, Maria Caroline ^a   Zamoner, Ariane ^a   Gottfried, Carmem ^a   Wajner, Moacir ^a   Pessoa Pureur, Regina ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

GFAP; Immunocytochemistry; Maple syrup urine disease; Phosphorylation

Indexed keywords

2 OXOACID; 2 OXOISOCAPROIC ACID; 2 OXOISOVALERIC ACID; 3 METHYL 2 OXOVALERIC ACID; AMINO ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN MONOCLONAL ANTIBODY; INTERMEDIATE FILAMENT PROTEIN; MONOCLONAL ANTIBODY; PHOSPHORUS 32; PHOSPHOSERINE; PHOSPHOSERINE MONOCLONAL ANTIBODY; TYLOXAPOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL FREE SYSTEM; CELL STRUCTURE; CONTROLLED STUDY; CYTOPLASM; CYTOSKELETON; GLIOMA CELL; IMMUNOCOMPETENCE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INTERMEDIATE FILAMENT; MAPLE SYRUP URINE DISEASE; METABOLITE; NONHUMAN; POLYMERIZATION; PROTEIN PHOSPHORYLATION; RAT; TIME; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CYTOSKELETON; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; KETO ACIDS; MAPLE SYRUP URINE DISEASE; PHOSPHORYLATION; RATS;

ACER;

EID: 25144493250     PISSN: 08857490     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11011-005-7208-x     Document Type: Article

References (38)

1. Benda, P., Lightbody, J., Sato, G., Levine, L., and Sweet, W. (1968). Differentiated rat glial cell strain in culture. Science 161:370-371.
2. 32P incorporation into intermediate filaments in cerebral cortex of rats. Neuroreport 11:3545-3550.
3. Chuang, D.T., and Shih, V.E. (2001). Maple syrup urine disease (branched-chain ketoaciduria). In (C.R. Scriver, A.L. Beaudet, W.L. Sly, and D. Valle, eds.), The Metabolic and Molecular Bases of Inherited Disease, 8th edn., McGraw-Hill, New York, pp. 1971-2005.
4. Dahl, D. (1981). The vimentin GFA protein transition in rat neuroglia cytoskeleton occurs at the time of myelination. J. Neurosci. Res. 6:741-748.
5. Eng, L.F., and Lee, Y.L. (1995). Intermediate filaments in astrocytes. In (B.R. Ransom and H. Akettenmann, eds.), Neuroglial Cells, Oxford University Press, New York, pp. 650-667.
6. Funchal, C., Dall Bello Pessutto, F., Vieira de Almeida, L.M., de Lima Pelaez, P., Oliveira Loureiro, S., Vivian, L., Wajner, M., and Pessoa-Pureur, R. (2004b). α-Keto-β-methylvaleric acid increases the in vitro phosphorylation of intermediate filaments in cerebral cortex of young rats through the gabaergic system. J. Neurol. Sci. 217:17-24.
7. Funchal, C., de Almeida, L.M., Oliveira Loureiro, S., Vivian, L., de Lima Pelaez, P., Dall Bello Pessutto, F., Rosa, A.M., Wajner, M., and Pessoa-Pureur, R. (2003). In vitro phosphorylation of cytoskeletal proteins from cerebral cortex of rats. Brain Research Protocols 11:111-118.
8. Funchal, C., de Lima Pelaez, P., Oliveira Loureiro, S., Vivian, L., Dall Bello Pessutto, F., Vieira de Almeida, L.M., Tchernin Wofchuk, S., Wajner, M., and Pessoa-Pureur, R. (2002). α-Ketoisocaproic acid regulates phosphorylation of intermediate filaments in postnatal rat cortical slices through ionotropic glutamatergic receptors. Dev. Brain Res. 139:267-276.
9. Funchal, C., Gottfried, C., Vieira de Almeida, L.M., Wajner, M., and Pessoa-Pureur, R. (2004a). Evidence that the branched-chain α-keto acids accumulating in maple syrup urine disease induce morphological alterations and death in cultured astrocytes from rat cerebral córtex. Glia 48:230-240.
10. Goldberg, W.J., Levine, K.V., Tadvalkar, G., Laws, E.R., and Bernatein, I. (1992). Mechanisms of C6-glioma cell and fetal cell astrocyte migration into hydrated collagen I gels. Brain Res. 581:81-90.
11. Haghighat, N., and McCandless, D.W. (1997). Effect of ammonium chloride on energy metabolism of astrocytes and C6-glioma cells. Metab. Brain Dis. 12:287-298.
12. Haghighat, N., McCandless, D.W., and Geraminegad, P. (2000). Responses in primary astrocytes and C6-glioma cells to ammonium chloride and dibutyryl cyclic-AMP. Neurochem. Res. 25:277-284.
13. Inada, H., Nagata, K.-I., Goto, H., and Inagaki, M. (2000). Regulation of intermediate filament dynamics: A novel approach using site- and phosphorylation state-specific antibodies. In (K.L. Carraway and C.A.C. Carraway, eds.), Cytoskeleton: Signalling and Cell Regulation, Oxford University Press, New York.
14. Inagaki, M., Gonda, Y., Nishizawa, K., Kitamura, S., Sato, C., Ando, S., Tanabe, K., Kikuchi, K., Tsuiki, S., and Nishi, Y. (1990). Phosphorylation sites linked to glial filament disassembly in vitro locate in a non-alpha-helical head domain. J. Biol. Chem. 265:4722-4729.
15. Inagaki, M., Matsuoka, Y., Isujimura, K., Ando, S., Tokui, T., Takahashi, T., and Inagaki, N. (1996). Dynamic property of intermediate filaments: Regulation by phosphorylation. Bioessay 18:481-487.
16. Inagaki, M., Nakamura, Y., Takeda, M., Nishimura, T., and Inagaki, N. (1994). Glial fibrillary acidic protein: Dynamic property and regulation by phosphorylation. Brain Pathol. 4:239-243.
17. Iqbal, K., Alonso, A.C., El-Akkad, E., Gong, C.X., Haque, N., Khatoon, S., Pei, J.J., Tsujio, I., Wang, J.Z., and Grundke-Iqbal, I. (2002). Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J. Mol. Neurosci. 19:95-99.
18. Jacque, C.M., Keyas, M., Poreau, A., Raoul, M., Collier, P., Racadot, J., and Baumann, N. (1979). GFAP and S-100 protein levels as an index for malignany in human gliomas and neurinomas. J. Natl. Cancer Inst. 62:479-483.
19. Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 277:680-685.
20. Lamb, N.J., Fernandez, A., Feramisco, J.R., and Welch, W.J. (1989). Modulation of vimentin containing intermediate filament distribution and phosphorylation in living fibroblasts by the cAMP-dependent protein kinase. J. Cell Biol. 108:2409-2422.
21. Land, J.M., Mowbray, J., and Clark, J.B. (1976). Control of pyruvate and β-hydroxybutirate utilization in rat brain mitochondria and its relevance to phenylketonuria in maple syrup urine disease. J. Neurochem. 26:823-830.
22. Levitt, P., and Rakic, P. (1980). Immunoperoxidase localization of glial fibrillary acidic protein in radial glial cells and astrocytes of the developing rhesus monkey brain. J. Comp. Neurol. 193:815-840.
23. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-267.
24. Mangoura, D., Sakellardis, N., Lones, J., and Vernadakis, A. (1989). Early and late passage C-6 glial cell growth: Similarities with primary glial cells in culture. Neurochem. Res. 14:941-947.
25. Messing, A., and Brenner, M. (2003). GFAP: Functional implications gleaned from studies of genetically engineered mice. Glia 43:87-90.
26. Parker, K.P., Norenberg, M.D., and Vernadakis, A. (1980). "Transdifferentiation" of C6-glial cells in culture. Science 208:179-181.
27. Pessoa-Pureur, R., Funchal, C., de Lima Pelaez, P., Vivian, L., Oliveira Loureiro, S., de Freitas Miranda, R., and Wajner, M. (2002). Effect of the branched-chain alpha-ketoacids accumulating in maple syrup urine disease on the high molecular weight neurofilament subunit (NF-H) in rat cerebral cortex. Metab. Brain Res. 17:65-75.
28. Pollenz, R.S., and McCarthy, K.D. (1986). Analysis of cyclic AMP-dependent changes in intermediate filament protein phosphorylation and cell morphology in cultured astroglia. J. Neurochem. 47:9-17.
29. Ryken, T.C., Turner, J.W., Hicklin, D.J., Miller, J.F., Bagenstoss, B.A., and Lin, R. (1987). Induction of cytoskeletal alterations in C6 glioma by glia maturation factor. Int. J. Dev. Neurosci. 5:215-225.
30. Schonberg, S., Schweiger, B., Schwahn, B., Schwarz, M., and Wendel, U. (2004). Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. Mol. Gen. Metab. 82:69-75.
31. Smith, Q.R., Momma, S., Aoyagi, M., and Rapoport, S.I. (1987). Kinetics of neutral amino acid transport acroos the blood-brain barrier. J. Neurochem. 49:1651-1658.
32. Snyderman, S.E., Norton, P.M., and Roitman, E. (1964). Maple syrup urine disease with particular reference to diet therapy. Pediatrics 34:454-472.
33. Steele, R.D. (1986). Blood-brain barrier transport of alpha-keto acid analogs of amino acids. Fed. Proc. 45:2060-2064.
34. Taketomi, T., Kunishita, T., Hara, A., and Mizushima, S. (1983). Abnormal protein and lipid compositions of the cerebral myelin of a patient with maple syrup urine disease. Jpn. J. Exp. Med. 53:109-116.
35. Tashian, R.E. (1961). Inhibition of brain glutamic acid decarboxilase by phenylalanine, valine, and leucine drivatives: A suggestion concerning the etiology of the neurological defect in phenylketonuria and branched-chain ketonuria. Metabolism 10:393-402.
36. Toda, M., Miura, M., Asou, H., Toya, S., and Uyemura, K. (1994). Cell growth supression of astrocytoma C6 cells by GFAP cDNA transfection. J. Neurochem. 63:1975-1978.
37. Treacy, E., Clow, C.L., Reade, T.R., Chitayat, D., Mamer, O.A., and Sciver, C.R. (1992). Maple syrup urine disease: Interrelations between branched-chain amino-, oxo-, and hydroxyacids; implications for treatment; associations with CNS dysmyelination. J. Inherit. Metab. Dis. 53(15):121-135.
38. Weinstein, D.E., Shelanski, M.L., and Liem, R.K. (1991). Suppression by antisense mRNA demonstrates a requirement for the glial fibrillary acidic protein in the formation of stable astrocytic processes in response to neurons. J. Cell Biol. 112:1205-1213.